MacroGenics' first product Ok'd by FDA, for breast cancer

 

• The FDA has approved MacroGenics' (NASDAQ:MGNX) Margenza (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens,
• Matgenza is the first product approved from MacroGenics’ pipeline.
• Product launch is anticipated in March of 2021.
• https://seekingalpha.com/news/3645126-macrogenics-first-product-okd-fda-for-breast-cancer